Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Accesswire November 4, 2022

Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates

Accesswire November 3, 2022

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Accesswire November 1, 2022

Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022

Accesswire October 27, 2022

Moderna Named a Top Employer by Science for Eighth Consecutive Year

Accesswire October 27, 2022

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union

Accesswire October 19, 2022

EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

Accesswire October 19, 2022

90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster

Accesswire October 19, 2022

Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries

Accesswire October 17, 2022

Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022

Accesswire October 13, 2022

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Accesswire October 12, 2022

Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

Accesswire October 12, 2022

Moderna exercises option to license proprietary targeting technology from Autolus

GlobeNewswire October 12, 2022

Moderna Creates New Executive Committee Role Ahead of New Product Launches

Accesswire September 29, 2022

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Accesswire September 28, 2022

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Accesswire September 12, 2022

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

Accesswire September 8, 2022

Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Accesswire September 6, 2022

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine

Accesswire September 1, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Accesswire September 1, 2022